GLP-1 / Weight Loss

Wegovy vs Saxenda: Which GLP-1 Obesity Drug Is More Effective?

Verdict Summary

Wegovy (semaglutide 2.4mg) produces significantly greater weight loss (~15% vs ~8%) and requires only once-weekly dosing. Saxenda (liraglutide) has a longer obesity-specific track record.

Medical Disclaimer: This comparison is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer →

At a Glance

DimensionWegovySaxenda
Active CompoundSemaglutide 2.4mgLiraglutide 3mg
DosingOnce weeklyOnce daily
Avg. Weight Loss~15%~8%
FDA Obesity Approval20212014

Wegovy Deep Dive

Wegovy's once-weekly dosing and superior efficacy have made it the preferred GLP-1 for obesity in most clinical guidelines. The STEP 8 trial directly comparing semaglutide to liraglutide showed semaglutide's clear superiority.

Saxenda Deep Dive

Saxenda (liraglutide 3mg) was the first daily GLP-1 approved for obesity. Despite lower efficacy than semaglutide, it remains a useful option for patients who cannot tolerate weekly injections or have insurance barriers to newer agents.

How to Choose

Choose Wegovy if…

  • You want the most effective GLP-1 option
  • Weekly dosing is convenient for your lifestyle
  • Cost per unit of weight loss is a consideration

Choose Saxenda if…

  • Daily dosing flexibility is preferred
  • You have had adverse reactions to semaglutide
  • Saxenda is covered by your insurance and Wegovy is not

Still Unsure?

Get a personalized recommendation

Take the 5-minute PeptidePilot quiz. Our algorithm evaluates your goals, body, and lifestyle to recommend the right peptide for you — vendor-neutral.

Frequently Asked Questions

More Comparisons